Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1274-1281

  Chuthapisith, Suebwong ^a,b   Bean, Beverley E ^c   Cowley, Gerard ^c   Eremin, Jennifer M ^c   Samphao, Srila ^c   Layfield, Robert ^b   Kerr, Ian D ^b   Wiseman, Janice ^c   El Sheemy, Mohamed ^c   Sreenivasan, Thiagarajan ^c   Eremin, Oleg ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Annexin A1; Annexin A2; Breast cancer; Neoadjuvant chemotherapy; Pathological response

Indexed keywords

ANNEXIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; LIPOCORTIN 1; LIPOCORTIN 2; PACLITAXEL;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANNEXIN A1; ANNEXIN A2; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 64349091540     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.12.026     Document Type: Article

References (37)

1. Chuthapisith S., Eremin J.M., El Sheemy M., and Eremin O. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 4 (2006) 211-219
2. Fisher B., Brwon A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
3. Kaufmann P., Dauphine C.E., Vargas M.P., et al. Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery. Am Surg 72 (2006) 935-938
4. Jones R.L., and Smith I.E. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 7 (2006) 869-874
5. Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Brit J Cancer 86 (2002) 1041-1046
6. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 (2002) 1456-1466
7. Chuthapisith S., Layfield R., Kerr I.D., Hughes C., and Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30 (2007) 1545-1551
8. Davies R., Budworth J., Riley J., Snowden R., Gescher A., and Gant T.W. Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Brit J Cancer 73 (1996) 307-315
9. Wosikowski K., Regis J.T., Robery R.W., et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 6 (1995) 1395-1403
10. Charafe-Jauffret E., Genestier C., Monville F., et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25 (2006) 2273-2284
11. Ross D.T., Scherf U., Eisen M.B., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24 (2000) 227-235
12. Lippman M.E., Allergra J.C., Thompson E.B., et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. New Engl J Med 298 (1978) 1223-1228
13. Gerke V., and Moss S.E. Annexins: from structure to function. Physiol Rev 82 (2002) 331-371
14. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., and Lage H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Meth 37 (1998) 105-116
15. Wang Y., Serfass L., Roy M.O., Wong J., Bonneau A.M., and Georges E. Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314 (2004) 565-570
16. Shen D., Nooraie F., Elshimali Y., et al. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Human Pathol 37 (2006) 1583-1591
17. Ahn S.H., Sawada H., Ro J.Y., and Nicolson G.L. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 15 (1997) 151-156
18. Alldridge L.C., and Bryant C.E. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res 290 (2003) 93-107
19. Vishwanatha J.K., Chiang Y., Kumble K.D., Hollingsworth M.A., and Pour P.M. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14 (1993) 2575-2579
20. Chen R., Brentnall T.A., Pan S., et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 6 (2007) 1331-1342
21. Zimmermann U., Woenckhaus C., Pietschmann S., et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 445 (2004) 368-374
22. Sharma M.R., Koltowski L., Ownbey R.T., Tuszynski G.P., and Sharma M.C. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81 (2006) 146-156
23. Sharma M.R., Rothman V., Tuszynski G.P., and Sharma M.C. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis lung carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. Exp Mol Pathol 81 (2006) 136-145
24. McColl B.K., Baldwin M.E., Roufail S., et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198 (2003) 863-868
25. Huang Y., Yin Y., Yang C.H., et al. Involvement of annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 309 (2008) 117-123
26. Lim L.H., and Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 21 (2007) 968-975
27. Fan X., Krahling S., Smith D., Williamson P., and Schlegel R.A. Macrophage surface expression of annexins I and II in the phagocytosis of apoptotic lymphocytes. Mol Biol Cell 15 (2004) 2863-2872
28. Erkizan O., Kirkali G., Yorukoglu K., and Kirkali Z. Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology 64 (2004) 474-478
29. Storm F.K., Mahvi D.M., and Gilchrist K.W. Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 3 (1996) 570-573
30. Thor A., Benz C., Moore D., et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83 (1991) 170-178
31. Zhang D., Wong L.L., and Koay E.S. Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer. Mol Cancer 6 (2007) 52
32. Laguens G.E., Coronato S., Spinelli O., Laguens R.P., and Di Girolamo W. Can breast cancer Hsp 27 (Heat Shock Protein 27,000) expression influence axillary lymph node status?. Breast 10 (2001) 179-181
33. Parekh H.K., Deng H.B., Choudhary K., Houser S.R., and Simpkins H. Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells. Biochem Pharmacol 63 (2002) 1149-1158
34. Tan Y., Li G., Zhao C., et al. Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leukemia Res 27 (2003) 125-131
35. Jackson J.R., Patrick D.R., Dar M.M., and Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat Rev Cancer 7 (2007) 107-117
36. Alli E., Bash-Babula J., Yang J.M., and Hait W.N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62 (2002) 6864-6869
37. Golouh R., Cufer T., Sadikov A., et al. The prognostic value of stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 110 (2007) 317-326